<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04866680</url>
  </required_header>
  <id_info>
    <org_study_id>ICL-2021-01</org_study_id>
    <nct_id>NCT04866680</nct_id>
  </id_info>
  <brief_title>Personalized Circulating DNA Follow-up in Melanoma (PERCIMEL)</brief_title>
  <acronym>PERCIMEL</acronym>
  <official_title>Personalized Circulating DNA Follow-up in Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de Lorraine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Cancérologie de Lorraine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PERCIMEL is an open multicentric study. The purpose of this study is to assess the interest&#xD;
      of molecular analysis on circulating tumor DNA in the follow-up of the disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2022</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Studying the tumor molecular abnormalities resulting from circulating tumor DNA (ctDNA) to predict the resistance to treatment</measure>
    <time_frame>24 months</time_frame>
    <description>Quantity of ctDNA / Resistance to treatment defined as a change in treatment decided during staff meeting</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Personalized Circulating DNA follow-up</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FFPE tissue sample + blood sample (20ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Personalized Circulating DNA follow-up</intervention_name>
    <description>FFPE tissue sample will be collected before and after surgery blood samples will be collected before and after surgery and every 3 to 4 months</description>
    <arm_group_label>Personalized Circulating DNA follow-up</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  locally advanced, operable melanoma&#xD;
&#xD;
          -  treated by immunotherapy or anti-BRAF and anti-MEK targeted therapies (stage IIIb,&#xD;
             IIIc) or exclusive immunotherapy (stage IV) in an adjuvant situation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  second cancer&#xD;
&#xD;
          -  woman who is pregnant, likely to be pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>MERLIN JEAN-LOUIS, PharmD, PhD</last_name>
    <phone>33 3 83 65 60 62</phone>
    <email>jl.merlin@nancy.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>HERMAN MARIE-AUDE</last_name>
    <phone>33 3 83 59 86 68</phone>
    <email>m.herman@nancy.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancerologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>MERLIN JEAN LOUIS, PharmD,PhD</last_name>
      <phone>00 33 3 83 65 60 62</phone>
      <email>jl.merlin@nancy.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>HERMAN MARIE-AUDE</last_name>
      <phone>00 33 3 83 59 86 68</phone>
      <email>m.herman@nancy.unicancer.fr</email>
    </contact_backup>
    <investigator>
      <last_name>GEOFFROIS LIONEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>HARLE ALEXANDRE, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 9, 2021</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Circulating tumour DNA</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>targeted therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

